Discover our vision and connect with us to start a partnership and project.
Samplix ApS empowers the life sciences and medical research communities with cutting-edge microfluidics-based solutions. At Samplix, our mission is to elevate the resolution and throughput of genomics, cell screening, and molecular engineering workflows, providing researchers with unparalleled insights into the intricate world of cells and genomes.
Our proprietary Samplix technology is meticulously crafted to offer targeted DNA and single-cell insights. Through the generation of highly stable microfluidic double-emulsion droplets, we encapsulate biological material with precision, including single-cells, organelles, and single molecules. These microfluidic wonders pave the way for a myriad of high-resolution downstream analyses, ranging from assessments of single-cell functional heterogeneity to the acceleration of enzyme engineering.
At Samplix, we are more than just developers of microfluidics solutions; we are dedicated partners ready to assist academic, corporate, and government researchers in achieving their goals. Our expertise extends across diverse fields such as human genomics, gene and cell therapy, plant genomics, and synthetic biology.
How do you get error- and bias-free identification of genomic variants? This was the question that Dr. Marie Just Mikkelsen and Dr. Thomas Kvist wanted to answer in 2012, when they were working on rare genomic variants. At the time, no existing technology could address that important question. Motivated by the challenge, the two scientists set out to develop a method that reveals any genomic variation.
PCR and unintended interactions between DNA molecules during sample handling are often the root of bias and errors in genomic analyses. Marie and Thomas built a team focused on creating a PCR amplification-free workflow with single molecules encapsulated in droplets.
In 2019, after 6 years of product development and thorough testing, the fully developed microfluidics system for droplet-based, PCR-free enrichment of genomic regions was launched under the name Xdrop®.
Since then, Xdrop technology has proven itself in a broad range of applications with human, other animal, plant, and microbial genomes. It also supports the investigation of cell reactions, including enzyme activity and protein synthesis.
With the success of the microfluidics system, Samplix has grown considerably, supporting customers worldwide with their genomics and molecular biology research.
CEO
Lars Kongsbak provides expertise in building startups, including strategy drafting and establish competent leadership. He has listed two life science companies and is or has been engaged with BlueBee, ViroGates, Exiqon, Novozymes and Novo Nordisk.
LI Logo svg original
CCO
Trine Overgaard Østerbye provides expertise in leading commercial operations in life sciences startup companies, including companies working within the areas of immunology other cell functionality space. She has been engaged with BioPorto Diagnostics, Svar Life Sciences, and Kementec Solutions.
Chief Development Officer, Product and Application Development
Peter Mouritzen provides expertise in documenting the many applications of the Xdrop technology and builds relationships with key opinion leaders across the globe. He has listed one life science company and has been engaged with QIAGEN and Exiqon.
VP Intellectual Property Rights
Søren Echwald Morgenthaler provides expertise in patent strategy, freedom to operate analysis and business strategy. He has listed one life sciences company and is or has been engaged with Anapa Biotech, Exiqon and Novo Nordisk.
Chairman & Co-Founder
Michael Obermayer is an experienced board member with extensive knowledge in Business Strategy, and Corporate Development. With previous roles at McKinsey & Co., and Fjord Capital Partners, Michael brings a wealth of global experience and strategic acumen to Samplix ApS.
Board member
Lars Krogsgaard is a professional board member with extensive experience in strategic development, business development, risk management, and financing. With a proven track record as an active investor and board member in over 25 Nordic companies, Lars brings valuable insights to Samplix ApS.
Henrik Christensen, Founder and CEO of Kementec Solutions, and serial entrepreneur, brings extensive expertise in biomedical and life sciences. He also holds key board positions, including Chairman of DiaLab and HC Handel & Invest. Henrik’s leadership is strengthened by his participation in INSEAD’s Advanced Board Program, fostering strategic business growth.
See the latest news about product releases, webinars and events, partnerships and more.
January 02, 2025 - Here are some of the conferences we'll be participating in the first half of 2025:
January 5, 2024 – In 2023, the EIC (European Innovation Council) committed to aiding Samplix in the development of our microfluidics technology for functional characterization of single cells. This technology is crucial for revealing the heterogeneity of immune cells fighting cancer, among other key applications. The incredible potential of cell and immune therapy is currently limited by technical challenges related to the standard analysis of immune cells in bulk, which neglects their heterogeneity.
Having made good progress in the EIC Accelerator-funded project in 2023, Samplix is opening 2024 with a tight focus on the ways our Xdrop instruments can best serve the cell therapy research community. We’re proud to have been chosen by the EIC and committed to ensuring vastly improved workflows for cell therapy research, including cytokine, granzyme, antibody, and cell killing applications.
Learn more
